| Abstract | Metronidazole has proven to be a useful and inexpensive antibiotic for the treatment of T. vaginalis and bacterial vaginosis. Few alternatives exist for these two specific indications, and metronidazole will continue to play a primary role in therapy. Oral metronidazole continues to be a very inexpensive alternative to oral vancomycin for the treatment of C. difficile-induced pseudomembranous colitis. For the treatment of moderate to severe mixed aerobic/anaerobic pelvic infections, metronidazole should be considered secondarily in patients who have failed other multiple- or single-drug regimens or in patients who are infected. with anaerobic organisms resistant to other commonly used agents including clindamycin, cefoxitin, cefotetan, or ampicillin/sulbactam. Metronidazole is not a first line drug of choice for antibiotic prophylaxis in obstetric and gynecologic patients. |
| Authors | W D Hager, R P Rapp
(Affiliation: Department of Obstetrics and Gynecology, University of Kentucky School of Medicine, Lexington.)
|
| Journal | Obstetrics and gynecology clinics of North America
(Obstet Gynecol Clin North Am)
Vol. 19
Issue 3
Pg. 497-510
(Sep 1992)
ISSN: 0889-8545 UNITED STATES |
| PMID | 1436927
(Publication Type: Journal Article, Review)
|
| Chemical References |
|
| Topics |
- Bacterial Infections
(drug therapy)
- Costs and Cost Analysis
- Drug Interactions
- Drug Resistance, Microbial
- Enterocolitis, Pseudomembranous
(drug therapy)
- Female
- Genital Diseases, Female
(drug therapy)
- Humans
- Metronidazole
(adverse effects, chemistry, therapeutic use)
- Pregnancy
- Pregnancy Complications, Parasitic
(drug therapy)
- Trichomonas Vaginitis
(drug therapy)
- Vaginosis, Bacterial
(drug therapy)
|
